A prospective, nationwide, multicentre, observational study to examine the efficacy, safety and immunogenicity of Inflectra®/CT-P13* (infliximab) in the induction treatment of CD and UC45.
Final results: 1 year follow-up in 229 patients
CRP reductions were maintained throughout 54 weeks23.
- Early clinical remission at 14 weeks
- Early clinical and biochemical response, immunogeicity and safety at 14 weeks
- Clinical response, remission and steroid-free remission at week 30
No new safety signals were detected during this study.
*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
CD, Crohn's disease; UC, Ulcerative colitis; CRP, C-reactive protein.
PP-IFA-GBR-0298. December 2018